
Elekta and Bristol Myers Squibb partner on digital solution for patients with melanoma

HELSINKI – Elekta (EKTA-B.ST) today announced a pilot collaboration with Bristol Myers Squibb to develop a digital solution for patients with melanoma. The collaboration leverages Elekta's digital health interventions platform, Kaiku Health, to facilitate communication between healthcare professionals and their patients on symptom management.

Elekta's digital solution will provide an accessible, user-friendly way for patients to share relevant information on their wellbeing with their care team, and to receive tailored support and guidance during treatment. By utilizing machine learning algorithms, the platform will enable real-time evaluation of patient-reported data, providing healthcare providers with personalized insights that may improve patients' care pathway and care experience.

"We are thrilled to collaborate with Bristol Myers Squibb to potentially advance the use of digital health interventions, such as in the treatment of melanoma," said Anish Patankar, SVP & Head of Business Line Software at Elekta. "By providing patients with the tools and support they need, we aim to empower them to actively participate in their treatment journey."

Through personalized symptom monitoring, healthcare professionals can react early and focus on what matters, while enabling their patients to take a more active role in their treatment. In the past two years, Elekta has also entered partnerships with Roche and Novartis to deploy digital tools to provide real-time symptom management by patients and health care providers.

To learn more about Kaiku Health visit www.elekta.com/kaiku.

#

For further information, please contact:

Mattias Thorsson, Vice President, Head of Corporate Communications
Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com
Time zone: CET: Central European Time

Raven Canzeri, Global Director, Media Relations
Tel: +1 770-670-2524, e-mail: Raven.Canzeri@elekta.com
Time zone: ET: Eastern Time

About Elekta

As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,500 employees combine passion, science, and imagination to profoundly change cancer care. We don't just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com or follow [@Elekta](https://twitter.com/Elekta) on "X", formerly known as Twitter.